A study has revealed that a combination of two FDA-approved drugs- rapamycin and trametinib -can extend lifespan of mice by up to 30%. The mice also exhibited improved health markers, including reduced inflammation, delayed tumour progression, and enhanced physical function. The combination of the drugs influences activity of genes differently than is achieved by administering them individually.